Scientist.com, Discovery aid liquid biopsy and immunotherapy research

LabPulse.com staff writers
Dec 3, 2020
2020 04 29 22 14 7161 Lab Blood Dropper V2 400

Discovery Life Sciences and outsourced research network provider Scientist.com are joining forces on technology services aiding liquid biopsy and immunotherapy studies.

Through the new offering, Illumina's TruSight Oncology 500 (TSO500) technology for formalin-fixed paraffin-embedded (FFPE) and circulating tumor DNA (ctDNA) services will be made available to Scientist.com users. The TSO500 technology has been incorporated into Discovery's HudsonAlpha Discovery sequencing and bioinformatics laboratory, and is available under one umbrella legal agreement, the companies noted.

Latest in Sequencing
Dna Sequencing Social
Labcorp launches liquid biopsy test for oncology
June 1, 2023
T Cell Social
Single-cell RNA sequencing data reveals T cells linked to cancer immunotherapy resistance
May 30, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
May 11, 2023
Crispr Cas9 Gene Editing Social
CRISPR-based technology shows promise for oral health assessment
May 16, 2023
Related Stories
2017 09 14 23 05 1167 Cancer Cell 400
CLIA
Lucence, Waseda University partner on liquid biopsy test
2019 04 27 00 03 6781 Dna Sequence Shadow 400
Guideline
Holy Grail: Ilumina nabs cancer testing firm in $8B deal
2019 07 26 20 46 7792 Lab Blood Woman 400
Infectious
Top 5 facts about the IVD market
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Sequencing
Labcorp launches liquid biopsy test for oncology
The test, called Labcorp Plasma Focus, enables treating oncologists to evaluate circulating cell-free DNA released by tumor cells.
June 1, 2023
Dna Sequencing Social
Single-cell RNA sequencing data reveals T cells linked to cancer immunotherapy resistance
Scientists at the University of Texas MD Anderson Cancer Center have provided a new explanation for why checkpoint inhibitors are ineffective in some patients.
May 30, 2023
T Cell Social
Illumina CEO remains on the board, chairman is voted out
Activist investor Carl Icahn, in a proxy fight, had urged the shareholders to remove the chairman and CEO from the board.
May 26, 2023
Sequencing Dna Rna Social
CRISPR-based technology shows promise for oral health assessment
CRISPR-based technology could be used to assess a range of oral and systemic diseases, say researchers from the Forsyth Institute.
May 16, 2023
Crispr Cas9 Gene Editing Social
Thermo Fisher Scientific, Pfizer collaborate to broaden NGS testing in underserved countries
Under the agreement, Thermo Fisher will select local labs for its NGS technology, ensuring they have the infrastructure, trained staff, and quality control measures to meet industry standards to conduct NGS testing for breast and lung cancer.
May 9, 2023
Sequencing Dna Rna Social
Experts advocate expanding newborn screening to cover treatable genetic childhood diseases
Increased knowledge of the genetic drivers for a broader range of diseases and the development of targeted medicines for them means it is now possible to screen and treat a wider range of conditions than is covered by current laboratory screening tests.
May 8, 2023
Baby Bottle Social
PacBio Q1 revenue rises 17%
The company received its first orders for the Onso short-read sequencing system and released new workflows in collaboration with Corteva Agriscience that enable the sequencing of thousands of plant and microbial genome samples annually.
May 2, 2023
Dna Sequencing2 Social
Illumina, Icahn issue letters to sequencing firm's shareholders, escalating proxy battle
Citing dissatisfaction with the way Illumina is being managed, Carl Icahn is engaged in a proxy contest with the DNA sequencing firm.
May 2, 2023
Business Regulation Graphic Social Resized
Illumina NGS instrument software vulnerable to cybersecurity breach: FDA
Though it has received no reports that anyone has exploited a vulnerability in Illumina’s instrument software, the FDA said the possible impact on genomic data includes causing instruments to provide no results, incorrect results, or altered results.
May 1, 2023
Artificial Intelligence Ai Hand Social
Devyser, Thermo Fisher ink collaboration, distribution agreement
The agreement gives Thermo Fisher Scientific the exclusive rights to commercialize Devyser's post-transplant portfolio of next-generation sequencing products in North America and Europe.
April 24, 2023
Dna Sequencing Genome Social
Oxford Nanopore, BioMérieux partner to develop infectious disease diagnostics
Initial areas of collaboration and joint development include a test for determining the antibiotic resistance of tuberculosis.
April 17, 2023
Sequencing Virus Social
Metagenomic sequencing in study cut time to identify antimicrobial resistance in bloodstream infections
Researchers at the University of Oxford said metagenomics could reveal the pathogens that are causing certain illnesses faster than a traditional two-step process.
April 17, 2023
Sequencing Dna Rna Social
Page 1 of 43
Next Page